A comparison of medical management with misoprostol and surgical management for early pregnancy failure

Jun Zhang, Jerry M. Gilles, Kurt Barnhart, Mitchell D Creinin, Carolyn Westhoff, Margaret M. Frederick

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

BACKGROUND: Misoprostol is increasingly used to treat women who have a failed pregnancy in the first trimester. We assessed the efficacy, safety, and acceptability of this treatment in a large, randomized trial. METHODS: A total of 652 women with a first-trimester pregnancy failure (anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion) were randomly assigned to receive 800 μg of misoprostol vaginally or to undergo vacuum aspiration (standard of care) in a 3:1 ratio. The misoprostol group received treatment on day 1, a second dose on day 3 if expulsion was incomplete, and vacuum aspiration on day 8 if expulsion was still incomplete. Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuum-aspiration group) within 30 days after the initial treatment constituted treatment failure. RESULTS: Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3 and 84 percent by day 8 (95 percent confidence interval, 81 to 87 percent). Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day 30. Hemorrhage or endometritis requiring hospitalization was rare (1 percent or less in each group), with no significant differences between the groups. In the misoprostol group, 78 percent of the women stated that they would use misoprostol again if the need arose and 83 percent stated that they would recommend it to others. CONCLUSIONS: Treatment of early pregnancy failure with 800 μg of misoprostol vaginally is a safe and acceptable approach, with a success rate of approximately 84 percent.

Original languageEnglish (US)
Pages (from-to)761-769
Number of pages9
JournalNew England Journal of Medicine
Volume353
Issue number8
DOIs
StatePublished - Aug 25 2005
Externally publishedYes

Fingerprint

Misoprostol
Pregnancy
Vacuum
First Pregnancy Trimester
Therapeutics
Confidence Intervals
Endometritis
Fetal Death
Spontaneous Abortion
Standard of Care
Treatment Failure
Hospitalization
Hemorrhage
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A comparison of medical management with misoprostol and surgical management for early pregnancy failure. / Zhang, Jun; Gilles, Jerry M.; Barnhart, Kurt; Creinin, Mitchell D; Westhoff, Carolyn; Frederick, Margaret M.

In: New England Journal of Medicine, Vol. 353, No. 8, 25.08.2005, p. 761-769.

Research output: Contribution to journalArticle

Zhang, Jun ; Gilles, Jerry M. ; Barnhart, Kurt ; Creinin, Mitchell D ; Westhoff, Carolyn ; Frederick, Margaret M. / A comparison of medical management with misoprostol and surgical management for early pregnancy failure. In: New England Journal of Medicine. 2005 ; Vol. 353, No. 8. pp. 761-769.
@article{455af0977f2a4eb983d44ecaec64e7ef,
title = "A comparison of medical management with misoprostol and surgical management for early pregnancy failure",
abstract = "BACKGROUND: Misoprostol is increasingly used to treat women who have a failed pregnancy in the first trimester. We assessed the efficacy, safety, and acceptability of this treatment in a large, randomized trial. METHODS: A total of 652 women with a first-trimester pregnancy failure (anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion) were randomly assigned to receive 800 μg of misoprostol vaginally or to undergo vacuum aspiration (standard of care) in a 3:1 ratio. The misoprostol group received treatment on day 1, a second dose on day 3 if expulsion was incomplete, and vacuum aspiration on day 8 if expulsion was still incomplete. Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuum-aspiration group) within 30 days after the initial treatment constituted treatment failure. RESULTS: Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3 and 84 percent by day 8 (95 percent confidence interval, 81 to 87 percent). Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day 30. Hemorrhage or endometritis requiring hospitalization was rare (1 percent or less in each group), with no significant differences between the groups. In the misoprostol group, 78 percent of the women stated that they would use misoprostol again if the need arose and 83 percent stated that they would recommend it to others. CONCLUSIONS: Treatment of early pregnancy failure with 800 μg of misoprostol vaginally is a safe and acceptable approach, with a success rate of approximately 84 percent.",
author = "Jun Zhang and Gilles, {Jerry M.} and Kurt Barnhart and Creinin, {Mitchell D} and Carolyn Westhoff and Frederick, {Margaret M.}",
year = "2005",
month = "8",
day = "25",
doi = "10.1056/NEJMoa044064",
language = "English (US)",
volume = "353",
pages = "761--769",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "8",

}

TY - JOUR

T1 - A comparison of medical management with misoprostol and surgical management for early pregnancy failure

AU - Zhang, Jun

AU - Gilles, Jerry M.

AU - Barnhart, Kurt

AU - Creinin, Mitchell D

AU - Westhoff, Carolyn

AU - Frederick, Margaret M.

PY - 2005/8/25

Y1 - 2005/8/25

N2 - BACKGROUND: Misoprostol is increasingly used to treat women who have a failed pregnancy in the first trimester. We assessed the efficacy, safety, and acceptability of this treatment in a large, randomized trial. METHODS: A total of 652 women with a first-trimester pregnancy failure (anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion) were randomly assigned to receive 800 μg of misoprostol vaginally or to undergo vacuum aspiration (standard of care) in a 3:1 ratio. The misoprostol group received treatment on day 1, a second dose on day 3 if expulsion was incomplete, and vacuum aspiration on day 8 if expulsion was still incomplete. Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuum-aspiration group) within 30 days after the initial treatment constituted treatment failure. RESULTS: Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3 and 84 percent by day 8 (95 percent confidence interval, 81 to 87 percent). Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day 30. Hemorrhage or endometritis requiring hospitalization was rare (1 percent or less in each group), with no significant differences between the groups. In the misoprostol group, 78 percent of the women stated that they would use misoprostol again if the need arose and 83 percent stated that they would recommend it to others. CONCLUSIONS: Treatment of early pregnancy failure with 800 μg of misoprostol vaginally is a safe and acceptable approach, with a success rate of approximately 84 percent.

AB - BACKGROUND: Misoprostol is increasingly used to treat women who have a failed pregnancy in the first trimester. We assessed the efficacy, safety, and acceptability of this treatment in a large, randomized trial. METHODS: A total of 652 women with a first-trimester pregnancy failure (anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion) were randomly assigned to receive 800 μg of misoprostol vaginally or to undergo vacuum aspiration (standard of care) in a 3:1 ratio. The misoprostol group received treatment on day 1, a second dose on day 3 if expulsion was incomplete, and vacuum aspiration on day 8 if expulsion was still incomplete. Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuum-aspiration group) within 30 days after the initial treatment constituted treatment failure. RESULTS: Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3 and 84 percent by day 8 (95 percent confidence interval, 81 to 87 percent). Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day 30. Hemorrhage or endometritis requiring hospitalization was rare (1 percent or less in each group), with no significant differences between the groups. In the misoprostol group, 78 percent of the women stated that they would use misoprostol again if the need arose and 83 percent stated that they would recommend it to others. CONCLUSIONS: Treatment of early pregnancy failure with 800 μg of misoprostol vaginally is a safe and acceptable approach, with a success rate of approximately 84 percent.

UR - http://www.scopus.com/inward/record.url?scp=23944478412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944478412&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa044064

DO - 10.1056/NEJMoa044064

M3 - Article

C2 - 16120856

AN - SCOPUS:23944478412

VL - 353

SP - 761

EP - 769

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -